Henlius Biotech shareholders reject take-private offer from China’s Fosun
Hong Kong shareholders of Shanghai Henlius Biotech on Wednesday rejected Chinese conglomerate Fosun International’s buyout offer, which would have valued the drugmaker at HK$13.37 billion ($1.72 billion).